Novartis (ADR) (NVS)
Develops innovative medicines across four therapeutic areas and multiple advanced technology platforms.
$141.28
After hours+0.01 (+0.01%)
At close$141.27(+0.21%)
Something off on this page? Send us feedback.
Next report
Oct 27, 26
in 35 days
EPS estimate
$2.24
Revenue estimate
$14.62B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Jan '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$1.98$2.28$2.42$2.25$2.03$1.99$2.41Pending
Estimate$1.80$2.12$2.38$2.26$1.99$2.11$2.17$2.24
Surprise+10.0%+7.5%+1.7%−0.4%+2.0%−5.7%+11.1%—
RevenueReportedEstimate
Jan '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$13.56B$13.62B$14.28B$14.36B$13.34B$13.11B$14.41BPending
Estimate$12.84B$13.90B$13.94B$13.64B$13.70B$13.44B$14.07B$14.62B
Surprise+5.6%−2.0%+2.5%+5.3%−2.7%−2.4%+2.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $2.46 | — | — |
| Sep 2027 | $2.59 | — | — |
| Jun 2027 | $2.63 | — | — |
| Mar 2027 | $2.34 | — | — |
| Dec 2026 | $2.19 | — | — |
| Oct 2026 | $2.24 | — | — |
| Jul 2026 | $2.17 | $2.41 | +11.1% |
| Apr 2026 | $2.11 | $1.99 | −5.7% |
| Feb 2026 | $1.99 | $2.03 | +2.0% |
| Oct 2025 | $2.26 | $2.25 | −0.4% |
| Jul 2025 | |||
| Apr 2025 | |||
| Jan 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Jan 2024 | |||
| Oct 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Jan 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Jan 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Jan 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $2.46 | — | — | $15.86B | — | — | — |
| Sep 2027 | $2.59 | — | — | $15.60B | — | — | — |
| Jun 2027 | $2.63 | — | — | $15.50B | — | — | — |
| Mar 2027 | $2.34 | — | — | $14.25B | — | — | — |
| Dec 2026 | $2.19 | — | — | $14.82B | — | — | — |
| Oct 27, 2026 | $2.24 | — | — | $14.62B | — | — | — |
| Jul 21, 2026 | $2.17 | $2.41 | +11.1% | $14.07B | $14.41B | +2.4% | +2.9% |
| Apr 28, 2026 | $2.11 | $1.99 | −5.7% | $13.44B | $13.11B | −2.4% | +0.9% |
| Feb 4, 2026 | $1.99 | $2.03 | +2.0% | $13.70B | $13.34B | −2.7% | +2.0% |
| Oct 28, 2025 | $2.26 | $2.25 | −0.4% | $13.64B | $14.36B | +5.3% | −4.4% |
| Jul 17, 2025 | |||||||
| Apr 29, 2025 | |||||||
| Jan 31, 2025 | |||||||
| Oct 29, 2024 | |||||||
| Jul 18, 2024 | |||||||
| Apr 23, 2024 | |||||||
| Jan 31, 2024 | |||||||
| Oct 24, 2023 | |||||||
| Jul 18, 2023 | |||||||
| Apr 25, 2023 | |||||||
| Feb 1, 2023 | |||||||
| Oct 25, 2022 | |||||||
| Jul 19, 2022 | |||||||
| Apr 26, 2022 | |||||||
| Feb 2, 2022 | |||||||
| Oct 26, 2021 | |||||||
| Jul 21, 2021 | |||||||
| Apr 27, 2021 | |||||||
| Jan 26, 2021 | |||||||
| Oct 27, 2020 | |||||||
| Jul 21, 2020 | |||||||
| Apr 28, 2020 | |||||||
| Jan 29, 2020 | |||||||
| Oct 22, 2019 | |||||||
| Jul 18, 2019 | |||||||
| Apr 24, 2019 | |||||||
| Jan 30, 2019 | |||||||
| Oct 18, 2018 | |||||||
| Jul 18, 2018 | |||||||
| Apr 19, 2018 | |||||||
| Jan 24, 2018 | |||||||
| Oct 24, 2017 | |||||||
| Jul 18, 2017 | |||||||
| Apr 25, 2017 | |||||||
| Jan 25, 2017 | |||||||
| Oct 25, 2016 | |||||||
| Jul 19, 2016 | |||||||
| Apr 21, 2016 | |||||||
| Jan 27, 2016 | |||||||
| Oct 27, 2015 | |||||||
| Jul 21, 2015 |